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Cognitive decline is one of the major causes of disability in older people. A high level of homocysteine, a 
byproduct of vitamin B, has been linked to brain atrophy, a precursor to cognitive decline leading to 
dementia and Alzheimer’s disease. In addition, a low level of vitamin B is often noted in patients with 
dementia and Alzheimer’s disease and its supplementation has been shown to improve memory and slow 
the progress of brain atrophy. This information may aid in the use of vitamin B as a preventative measure 
of severe cognitive decline, and thus reduce the onset of conditions such as, dementia and Alzheimer’s 
disease. 
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1. Introduction  
 All ageing humans will develop some degree of decline in cognitive capacity which predisposes 
some individuals to neurological and psychiatric disorders leading to poor quality of life [1]. Cognitive 
decline during ageing is multi-factorial, however, this paper focuses on the role of vitamin B during this 
process. Ageing deteriorates neuronal membranes (loss of myelin sheath) resulting in impaired 
neurotransmitter synthesis, signaling and overall diminished neuronal function [1]. Over time, symptoms 
include forgetfulness, inability to focus and decreased problem solving skills. Symptoms may progress to 
anxiety, depression, dementia and Alzheimer’s disease (AD) [2]. Currently there are no drugs or other 
treatments specifically approved to treat cognitive impairment or prevent its progression. 
  
2. Methodology  
 Herein, we present a vitamin B perspective in cognitive decline, using PubMed searches with the 
following key terms: dementia AND (vitamin B1 OR thiamine), dementia AND (vitamin B2 OR riboflavin), 
dementia AND (vitamin B6 OR pyridoxine), dementia AND (vitamin B9 OR folate OR folic acid), dementia 
AND (vitamin B12 OR cobalamin), cognitive decline AND (vitamin B1 OR thiamine), cognitive decline 
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AND vitamin B2 OR riboflavin), cognitive decline AND (vitamin B6 OR pyridoxine), cognitive decline AND 
(vitamin B9 OR folate OR folic acid), cognitive decline AND (vitamin B12 OR cobalamin), homocysteine 
AND vitamin B, homocysteine AND dementia, Alzheimer’s AND vitamin B. In particular, publications from 
2006-2016 are mostly cited. 
 
3. Dementia and Alzheimer’s disease 
 Dementia is a term used for a particular set of cognitive decline symptoms, which often occur with 
ageing, and includes impaired thinking and memory. There are many different kinds of dementia, the 
most common is Alzheimers diseases which contributes to 60-70% of cases worldwide (Fig 1). Other 
forms include vascular dementia, dementia with lewy bodies and dementia caused by diseases, such as, 
Huntington’s, Parkinson’s, Creutzfeldt-Jakob’s. The process of ageing in humans leads to changes in 
brain morphology and function, which in turn can lead to an increased risk of disorders of a psychiatric 
and neurological nature. In fact, over 540 genes have been identified as age-related changes, and 
changes are progressive throughout adult life which can accurately predict the age of an individual [3]. 
Interestingly, most age-related genes to be up regulated are of inflammatory and glial origin, whereas, 
those to be down regulated are mostly cell communication and signaling origin. It is still unclear however, 
as to how the relationship between ageing and the clinical and molecular features of cognitive diseases 
such as, dementia and AD are linked. It has been postulated that an increase in life expectancy in 
western cultures has coincided with an increase in the prevalence of cognitive impairments (dementia, 
AD etc), and perhaps this is less about disease process and more about the natural process of ageing [4]. 
 AD has been described as the most common disease of ageing. Patients with AD suffer a 
progressive cognitive decline, and, an inability to form memories. The gradual diminishing of intellectual 
function eventually leads to complete dependence for all basic life functions and eventual death at a 
premature age [5].  There are numerous incongruent leads into the pathogenesis of AD. The first 
histopathological features recognized were the presence of extracellular amyloid plaques and intracellular 
neurofibrillary tangles. Aneuploidy, synaptic degeneration and hippocampal neuronal loss later became 
distinguishing features of AD. In fact, post-mortem studies of AD patients, find the existence of these 
histopathological features in up to 90 % of cases [4]. Mitochondrial dysfunction is also implicated in AD, 
including, amyloidosis (Aβ), oxidative stress, tau phosphorylation and cell cycling [6]. Further, vascular 
disease increases Alzheimer’s risk. A common finding amongst older adults who meet the 
neuropathological criteria for AD is the occurrence of cerebral amyloid known as angiopathy. This 
condition is characterised by Aβ deposits in cerebral blood vessel walls, which leads to intracerebral 
hemorrhages and impact cerebrovascular function. This occurs as a result of weakening of vessel walls, 
which can lead to rupture  [7].  
  
4. Risk factors contributing to cognitive decline  
 A number of contributing factors have been associated with cognitive decline in humans. Such 
factors include: suboptimal nutrition, physical inactivity and sedentary lifestyle, obesity, smoking, 
hormonal imbalances, low-grade chronic inflammation, oxidative stress and free radical damage to the 
myelin sheath, cerebrovascular health, high density lipoprotein levels, high cholesterol levels, high 
homocysteine levels, hypertension, impaired blood glucose and depression [8]. There are certain dietary 
considerations for improved cognitive function, which include: moderate coffee and red wine intake, fish 
oil, polyphenols and anthocyanin-containing foods (tea, blueberries, resveratrol), coenzyme Q10, acetyl-
L-carnitine, ginkgo bilboa and multi-vitamins – in particular B vitamins. 
 
 3 
4.1 The relationship between serum homocysteine in dementia and AD 
 Epidemiological evidence and longitudinal data flag elevated serum homocysteine as a probable 
risk factor for cognitive impairment and AD [9]. Homocysteine is a product of the methylation cycle and 
has been linked to brain atrophy, oxidative stress, DNA damage, increased apoptosis, excitotoxicity and 
neurodegeneration [9-11]. Methylation is the mechanism by which the body deals with stress, toxins and 
infections. The methylation pathway deals with the balancing of neurotransmitters and detoxification 
processes in the body, and controls inflammation. Methylation reactions are involved in almost every 
chemical reaction undertaken within the body (Fig 2). The result of ineffective methylation reactions within 
the body is widespread and can result in many health conditions and diseases, including neurological 
disorders such as anxiety, depression, bipolar disorder, AD, fibromyalgia, neural tube defects, 
schizophrenia and sleep disorders [12]. 
 The enzyme methionine synthetase catalyzes the methylation of homocysteine to methionine (Fig 
2) [13]. The failure of this reaction to take place effectively leads to an increase in blood levels of 
homocysteine, which can cause metabolic impairment. Several neurodegenerative disorders including 
Parkinson’s, AD, depression and dementia are characterized by increased homocysteine levels [13]. The 
toxic effect to vascular endothelial and neuronal cells caused by homocysteine elevation is well 
documented [14, 15]. In order for homocysteine levels to remain low in the central nervous system, an 
adequate amount of folate is required in the diet, as folate is essential in the methylation of homocysteine 
to methionine and in the synthesis of S-adenosyl-methionine, which is required for methylation of DNA, 
proteins and lipids. Several studies have shown that serum homocysteine are  significantly higher, and 
serum folate and vitamin B12 levels lower, in patients with dementia and AD patients [16]. In fact, high 
homocysteine levels increases risk of brain atrophy which is exacerbated by alcohol [9].  
The status of B vitamins is frequently inadequate in the elderly and several studies have shown 
decreases in cognitive function, which may lead to AD [11]. This leads to the question - would inadequate 
vitamin B levels contribute to brain malfunctions or are brain malfunctions a result of the ageing process 
leading to disease?  In 107 individuals aged between 60-87 years of age who did not present with 
symptoms of cognitive impairment, those with lower vitamin B12 and holotranscobalamin (active form of 
B12) and higher plasma total homocysteine, had a greater decrease in brain volume over a 5 year follow-
up period [17]. However, in the Rotterdam study, in 702 individuals aged 55 years and over, there was no 
difference in patients with higher homocysteine and cognitive decline [18]. This study was carried out over 
a shorter period, with the mean duration of follow up being 2.7 years. It is possible that the time period for 
follow up was too short to note any significant change in cognitive decline. The age cut off for the patients 
in this study was 55 years which is considerably lower than in the previous study in which the age of 
patients was between 60-87 years of age.  
  
5.  B vitamins: link to cognitive decline  
 Vitamins are dietary components other than carbohydrates, fats, minerals and proteins that are 
necessary for life. Vitamin B complex plays an important role in the functioning of the methylation cycle, 
involved in monoamine oxidase production, synthesis of DNA, RNA, protein and phospholipids, and in 
cell repair. The role of the methylation cycle in detoxification of the body ensures proper immune function 
and inflammatory balance, maintains DNA, provides energy and balances mood behaviors [19]. 
Homocysteine, which is solely a product of the methylation cycle acts as a sensitive marker of vitamin B 
deficiencies [13]. Indeed, low levels of vitamin B1, B2, B6, B9 and B12 result in elevated homocysteine 
levels and predicts cognitive decline [20]. 
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5.1 Vitamin B1; Thiamine  Thiamine, a water soluble vitamin B, aids in the production of energy from carbohydrates in cells 
and is essential in the proper functioning of the nervous system. One of the earliest examples of a 
nutrition deficiency was the link between thiamine deficiency and neurological problems, including that of 
cognitive deficits. In fact, deficiency in thiamine is highly prevalent in older adults in particular hospitalised 
and institutionalised patients, and is associated with higher levels of depression and AD [21]. Further, in 
non-demented volunteers over 60 years of age, low thiamine levels were associated with lower mini-
mental state examination (MMSE) scores compared to those with high thiamine concentrations. Hence, 
low thiamine levels impact on cognitive function. In addition, rats fed on a thiamine deficient diet showed 
slower response time to an electrical impulse compared to control rats [22]. Repetitive thiamine deficiency 
in rats causes impaired cognition and brain damage [23]. Despite positive evidence suggesting a link 
between thiamine deficieney and risks of cognitive decline, there is still much work required, to determine 
whether thiamine supplementation would be beneficital as a preventative measure for cognitive decline. 
In particular, given the recent cross-sectional and case control studies reporting that high dietary thiamine 
intake has a beneficial effect on cognitive function is inconclusive [24].  
5.2 Vitamin B2; Riboflavin 
 Riboflavin or vitamin B2, is a precursor for Flavin adenine dinucleotide (FAD). Riboflavin plays a 
vital role in the intermediary metabolism of carbohydrates, amino acids and lipids. Due to its ability to play 
a role in both one and two electron transfer processes, deficiency of riboflavin manifests first within 
tissues of rapid cellular turnover such as skin and epithelium. This leads to inflammation of membranes of 
the mouth, skin, eyes and gastrointestinal tract. In a meta-analysis systemic review study on the 
micronutrient intake of older adults, it was shown  that deficiencies in riboflavin and thiamin were linked 
with poor cognitive outcomes [25]. Interestingly, a link between riboflavin and vitamin D metabolism and 
insufficient riboflavin availability and imbalance of FAD results in a distinct alteration in structure within the 
skeletal and central nervous systems [26]. FAD is a coenzyme of methylenetetrahydrofolate reductase 
(MTHFR). MTHFR is a catalyst for the formation of 5-methylenetetrahydrofolate which in turn assists 
homocysteine re-methylation by acting as a methyl donor. Riboflavin and folate act synergistically aiding 
in lower plasma homocysteine levels [27]. In fact, it was noted in a cohort of 126 healthy individuals who 
were supplemented with folate, that both folate and riboflavin interacted to decrease plasma 
homocysteine levels likely by increasing the catalytic activity of MTHFR [27]. In addition, riboflavin 
deficiency causes higher homocysteine levels in patients who carry the variant MTHFR 677T allele (a 
mutant form of the MTHFR gene which affects the conversion of dietary folate into the active form) 
regardless of folate status. There was no effect on homocysteine when vitamin B12 (cobalamine) levels 
were normal or elevated, thus, suggesting the importance of balance in overall vitamin B status [28]. 
Furthermore, low levels of dietary intake of riboflavin results in worse cognitive outcomes as assessed by 
the Halstead-reitan categories test (non-verbal test of abstract thinking ability) in 260 individuals over the 
age of 60 [29]. 
 
5.3 Vitamin B6; Pyridoxine  
 Vitamin B6 (comprising 3 chemically distinct compounds: pyridoxine, pyridoxal and pyridoxamine) 
is imperative in the regulation of mental function and plays a role in homocysteine re-methylation. It 
impacts on neurotransmitters which control depression, pain perception and anxiety. Its deficiency results 
in high homocysteine levels and has been linked to seizures, migraines, cognitive impairment, AD and 
other forms of dementia. In fact, in 140 individuals who were evaluated by the major depression inventory 
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scale, there was a clear correlation between cognitive function, depression and pyridoxine levels [30]. 
Supplementation of vitamin B6 reduces homocysteine blood levels and improves mood, psychotic 
symptoms in schizophrenia, cognitive function [31] and enhances long term memory [32]. Likewise, high 
vitamin B doses, of B6, B9 and B12 in elderly subjects with increased dementia risk (mild cognitive 
impairment based on the Petersen scale), reduced up to 7-fold the amount of cerebral atrophy in grey 
matter of the brain (key regions associated with AD and dementia), particularly in subjects with high 
homocysteine levels, thereby slowing cognitive decline [33]. However, even though supplementation of 
vitamin B6, B9 and B12 lowers homocysteine levels which could delay or prevent decline in cognition, 
such supplementation has no effect on atherosclerotic lesions in subjects with hyperhomocysteinemia 
[34]. Interestingly, in animal studies, pyridoxine supplementation does not improve learning and cognitive 
outcomes, but low levels of serum pyridoxine are linked to worse motor skills [32].  
 
5.4 Vitamin B9; Folate 
 Vitamin B9 (folate) is required for the synthesis, repair and methylation of DNA and contributes to 
a number of biological reactions. Folate is naturally found in foods, however, folic acid is an oxidised 
synthetic form of folate (chemically synthesised in 1943) and often used for fortification of foods 
(introduced in 1998 as mandatory). Despite folic acid being imperative in reducing neural tube defects 
and reducing homocysteine serum levels, there is a concern that it may have negative effects in the 
incidence of colon cancer [35]. Likewise, fortified flour, which has increased levels of folic acid to normal 
natural folate levels, causes an imbalance and affects negatively affects methylation reactions [36]. 
However, there is a positive association between low levels of folate and cognitive decline. In a study of 
166 patients diagnosed with either dementia, AD, it was found that levels of folate were consistently and 
significantly higher in the control group than in patients already suffering from a cognitive disease, 
indicating that folate supplementation in the elderly may be of prime importance in preventing common 
forms of dementia [37]. In addition, folic acid supplementation, together with pyridoxine and vitamin B12 
supplementation in individuals over 70 years old with mild cognitive impairment, showed slower rates of 
brain atrophy [38] and enhanced verbal delayed recall, global cognition and clinical dementia rating scale 
[39], in those that also had high serum omega-3 fatty acids levels. This highlights the importance of the 
inclusion of both omega-3 fatty acids and B vitamins in the diet for prevention of cognitive decline; 
although a clinical trial with vitamin B and omega-3 fatty acids is required to determine whether the 
combination is able to slow the conversion from mild cognitive impairment to AD. Recently, it was 
reported that a nutraceutical formulation, consisting of folate and vitamin B12 amongst others, 
significantly improved cognitive performance and behavioral and psychological symptoms of dementia in 
24 patients with AD [40]. Similarly, in the HAPIEE (health, alcohol and psychosocial factors in Eastern 
Europe) study comprising 4,166 participants, folate and vitamin B12 were positively associated with 
performance (verbal fluency, immediate recall) [41]. In addition, in 7,030 postmenopausal women without 
memory cognitive impairment or probable dementia, monitored for over 5 years, those with folate intake 
below the recommended daily allowance were associated with increased risk of mild cognitive impairment 
and probable dementia [42].  Conversely, a 2 year folic acid and vitamin B12 supplementation study in 
2,919 individuals over 65 years of age with high homocysteine levels, showed no beneficial effects on 
performance on 4 cognitive domains, although a small improvement in global cognition was noted [43].  
 
5.5 Vitamin B12; Cobalamin 
 Vitamin B12 (cobalamin) plays a major role in the normal functioning of the brain and the nervous 
system. It is involved in cellular metabolism of carbohydrates, proteins and lipids, and acts as a co-factor 
in myelin formation and the normal physiology of the nervous system. Vitamin B12 deficiency results in 
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severe symptoms of depression, suicidal behaviors, mania, psychosis and cognitive decline. Low levels 
of cobalamin increase the risk of cognitive decline, dementia and AD and is linked to a 5-fold increase in 
the rate of brain atrophy. In fact high vitamin B12 levels protect against brain atrophy associated with AD 
and cognitive decline [17]. Vitamin B12 methylation reactions affect homocysteine levels, and vitamin B12 
deficiency is one of the most common causes of hyperhomocysteinemia which has been associated with 
increased risk of dementia, in particular AD. The most common cause of B12 deficiency in the elderly is 
an inability to absorb B12 in the gastrointestinal tract. It has been shown that there is a significant 
association between brain size and vitamin B12 status in individuals between 61 - 87 years of age [17]. 
However, a literature search of all published data between 2002-2012 showed 7 systemic reviews and 11 
observational studies on the link between vitamin B12, homocysteine status and cognitive decline, 
indicated that there is an association between high homocysteine concentrations and the onset of 
dementia (low quality evidence). Based on low-moderate quality evidence vitamin B12 (and folate) 
supplementation seems slows the rate of brain atrophy, a precursor of dementia and AD [44].  
 
6.  Conclusion and future prospects  Cognitive decline leading to dementia and AD affects a growing number of people every year 
including the families whom are left to care for them. The cause of this disease is thought to be 
multifaceted involving lifestyle factors such as diet, smoking, alcohol consumption, as well as other 
medical conditions like diabetes, cerebrovascular disease, hypertension and traumatic brain injury (Fig 3). 
There is much documented evidence however, that increased homocysteine levels and deficiency of 
certain B vitamins contribute significantly to the pathophysiology and onset of the disease and its 
progression. Further research into this disease in terms of the methylation, serum homocysteine levels 
and supplementation with B vitamins, may uncover hope for new treatment modalities or provide greater 
insight into preventative measures and predictions of groups at risk for the onset of the disease. However, 
the association between vitamin B (B1, B2, B6, B9, B12) and the immune system on cognitive changes, 
requires further research (Fig 3). Further studies are therefore required to determine the link between 
vitamin B, immune system and cognitive decline. 
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Figure 1. The % occurance of dementia subtypes according to an updated research report  
  commissioned by Alzheimer’s Society on Dementia UK [45]. 








Figure 2. The methionine and folate cycles showing their interaction and vitamin B6, B9 and B12  
  involvement. Abbreviations: CBS, cystathionine h-synthase; MTHFR,    






Figure 3. The complexity of cognitive decline. Is there a link between vitamin B deficiency,   
  cognitive decline and the immune system? 
 
 
 
 
 
